Bortezomib + tipifarnib

Bortezomib + tipifarnib is an investigational combination therapy involving two small molecule drugs with distinct mechanisms of action, primarily studied in hematologic malignancies such as multiple myeloma and acute leukemias. Bortezomib is a proteasome inhibitor that disrupts protein degradation, leading to accumulation of misfolded proteins and apoptosis in cancer cells. Tipifarnib is a farnesyltransferase inhibitor that blocks the post-translational modification (farnesylation) of proteins involved in cell signaling, notably those required for membrane localization and function. The combination has shown synergistic effects by dual inhibition of the proteasome and aggresome pathways—tipifarnib downregulates HDAC6, disrupting aggresome formation, while bortezomib inhibits proteasomal degradation—resulting in enhanced accumulation of ubiquitinated proteins and increased apoptosis via both caspase-dependent and independent mechanisms. Clinical studies have demonstrated tolerability and preliminary efficacy signals in relapsed or refractory multiple myeloma and advanced leukemias[1][2][3][4].

Brand names

Velcade (for bortezomib)

Other names

None